Breast Cancer Working Conference, 3–6 September 1991, LeuvenSystemic treatment for locally advanced breast cancer: What we still need to learn after a decade of multimodality clinical trials
References (50)
- et al.
Survival following mastectomy for stage III breast cancer
Am J Surg
(1979) - et al.
Locally advanced breast cancer. The contribution of cytotoxic and endocrine treatment to radiotherapy
Eur J Cancer Clin Oncol
(1989) - et al.
Phase I-II study of concurrent irradiation and multi-drug chemotherapy in advanced carcinoma of the breast: A pilot study by the Southeastern Cancer Study Group
Int J Radiat Oncol Biol Phys
(1979) - et al.
Granulocyte-macrophage colony-stimulation factor to harvest circulating hematopoietic stem cells for autotransplantation
Lancet
(1989) - et al.
Management of locally advanced and inflammatory carcinoma of the breast
Surg Gynecol Obstetr
(1985) The treatment of locally advanced breast cancer
J Clin Oncol
(1984)- et al.
Treatment of stage III breast cancer. A panel discussion
Breast Cancer Res Treat
(1989) - et al.
Locally advanced breast cancer: current status and future directions
Int J Radiat Oncol Biol Phys
(1989) - et al.
Treatment of patients with inflammatory breast cancer
Why do we need systematic overviews of randomized trials?
Stat Med
Adjuvant chemo- and hormonal therapy in locally advanced breast cancer: a randomized clinical study
Int J Radiat Oncol Biol Phys
Adjuvant post-operative radiotherapy, chemotherapy and immunotherapy
Cancer
The management of non-resectable (stage III) breast cancer
Six-year results of a multimodality treatment strategy for locally advanced breast cancer
Cancer
Concurrent radiochemotherapy in advanced breast cancer
Cancer
Combined chemotherapy — radiotherapy approach in locally advanced (T3b-T4) breast cancer
Cancer Chemother Pharmacol
Prognostic factors in locally advanced inflammatory breast cancer — long-term results following primary chemotherapy
Breast Cancer Res Treat
Comparison of two adjuvant chemotherapy programs for locally advanced breast cancer: a prospective randomized trial
Neoadjuvant chemotherapy or chemotherapy and endocrine therapy in locally advanced breast carcinoma
Am J Clin Oncol
Tamoxifen versus chemotherapy as adjuvant treatment in stage III breast cancer
Aust NZ J Surg
Preoperative chemotherapy in the treatment of inflammatory breast cancer
The management of nonmetastatic locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery
World J Surg
Neoadjuvant chemotherapy in the combined modality approach of locally advanced non metastatic breast cancer
Chemotherapy with estrogenic recruitment in locally advanced and metastatic breast cancer: results of two randomized trials
Cited by (17)
Primary systemic treatment and concomitant low dose radiotherapy for breast cancer: Final results of a prospective phase II study
2014, BreastCitation Excerpt :Primary systemic treatment is the standard for management of stage IIA-IIB/IIIA breast cancer. Primary aim is the achievement of a pCR, which is correlated to a better 10-year OS and DFS and a lower risk of recurrences [3–5]. A wide variety of chemotherapy regimens have been used as preoperative treatment, with most incorporating doxorubicin.
Selective Mastectomy in the Management of Locally Advanced Breast Cancer
2007, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :Local disease was most likely to be symptomatic at death when the primary tumor was ≥10 cm. Induction chemotherapy (and less often hormonal therapy) is now the standard of care in the management of LABC (33–38). Initial systemic therapy is a means of rendering a patient operable (35), as well as dealing with micrometastatic disease as soon as possible.
Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx®) and paclitaxel in locally advanced breast cancer: A phase II study by the Hellenic Cooperative Oncology Group
2002, Annals of OncologyCitation Excerpt :A wide variety of chemotherapy regimens have been used as preoperative treatment, with most incorporating doxorubicin. These regimens generally produce a response rate in at least two-thirds of patients with a complete pathological remission rate of approximately 10–15% [1]. Anthracyclines such as doxorubicin are considered among the most active single agents in advanced breast cancer.
Primary chemotherapy in breast cancer
1998, Biomedicine and Pharmacotherapy